Direct-to-Consumer Testing (DTC): Destined to Connect or Disrupt. Buyer Be Aware (An Infectious Disease Perspective)

Duque, Teofilo Borunda; Dodd, Monique; Ali, Ramisha; VanNess, Richard; Grenache, David G.

doi:10.1016/j.clinmicnews.2022.02.001

Cited by 2 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 Cases of delayed notification to the appropriate jurisdiction have also been described. 22 Finally, there is no mechanism in this process for partner management. Although remote testing may be an excellent option for expanding the reach of providers and DIS, the direct-toconsumer approach needs refinement.…”

Section: Chlamydia Gonorrhea and Trichomonasmentioning

confidence: 99%

See 1 more Smart Citation

Testing Technologies as Enhancers of Disease Intervention Specialist Activities: Applying Lessons From COVID-19

Pol

2022

Sexual Trans Dis

View full text Add to dashboard Cite

Disease intervention specialists are often at the forefront of adoption of new technologies in support of sexually transmitted infection (STI) contact tracing efforts. Newer technology for detection of treatable STI includes point-of-care molecular tests for detection of chlamydia, gonorrhea, and trichomonas and syphilis serology point-of-care tests. Other additions to our case finding toolbox are the use of telemedicine and the proliferation of direct-to-consumer offerings, both of which rely on remote sample collection involving self-collection of specimens in nonclinical settings. Finally, on the near horizon are over-the-counter tests that will support self-testing without the involvement of a medical professional. Each of these new developments is discussed and contextualized in experiences resulting from the COVID-19 pandemic response. Many options are now available, or will be soon, for detection of STIs in nontraditional settings, and we need to consider the processes involved as we move toward adoption of these new tools.

show abstract

Section: Chlamydia Gonorrhea and Trichomonasmentioning

confidence: 99%

“…Furthermore, the interaction with a provider is often remote, and cases of inappropriate treatment have been described 21 . Cases of delayed notification to the appropriate jurisdiction have also been described 22 . Finally, there is no mechanism in this process for partner management.…”

Section: Currently Available Optionsmentioning

confidence: 99%

Testing Technologies as Enhancers of Disease Intervention Specialist Activities: Applying Lessons From COVID-19

Pol

2022

Sexual Trans Dis

View full text Add to dashboard Cite

show abstract

“…Most DTC tests mention this in their terms and agreement section which is most often not read by consumers in their anxiety and hurry to perform the test. 5,[8][9][10]…”

Section: Privacy Issuesmentioning

confidence: 99%

Universal Coronavirus Testing to Control the Pandemic: Ethical Issues and Dilemmas

Gopinathan¹,

Naik²,

Maheswary³

et al. 2022

J. Pure Appl. Microbiol.

View full text Add to dashboard Cite

Every country had to make several difficult decisions in the initial phase of the Coronavirus (COVID-19) pandemic to allocate resources for COVID testing. Decisions on who should be tested for COVID-19 testing are extremely vital for pandemic preparedness. In this article, we highlight the need for prioritization of testing resources including direct-to-consumer testing methods, ethical dilemmas involved in obligatory testing, and testing of refugees and immigrants.

show abstract

Direct-to-Consumer Testing (DTC): Destined to Connect or Disrupt. Buyer Be Aware (An Infectious Disease Perspective)

Cited by 2 publications

References 12 publications

Testing Technologies as Enhancers of Disease Intervention Specialist Activities: Applying Lessons From COVID-19

Testing Technologies as Enhancers of Disease Intervention Specialist Activities: Applying Lessons From COVID-19

Universal Coronavirus Testing to Control the Pandemic: Ethical Issues and Dilemmas

Contact Info

Product

Resources

About